Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Genes Brain Behav ; 22(6): e12865, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37705179

ABSTRACT

Variations in the Dlg2 gene have been linked to increased risk for psychiatric disorders, including schizophrenia, autism spectrum disorders, intellectual disability, bipolar disorder, attention deficit hyperactivity disorder, and pubertal disorders. Recent studies have reported disrupted brain circuit function and behaviour in models of Dlg2 knockout and haploinsufficiency. Specifically, deficits in hippocampal synaptic plasticity were found in heterozygous Dlg2+/- rats suggesting impacts on hippocampal dependent learning and cognitive flexibility. Here, we tested these predicted effects with a behavioural characterisation of the heterozygous Dlg2+/- rat model. Dlg2+/- rats exhibited a specific, mild impairment in reversal learning in a substrate deterministic bowl-digging reversal learning task. The performance of Dlg2+/- rats in other bowl digging task, visual discrimination and reversal, novel object preference, novel location preference, spontaneous alternation, modified progressive ratio, and novelty-suppressed feeding test were not impaired. These findings suggest that despite altered brain circuit function, behaviour across different domains is relatively intact in Dlg2+/- rats, with the deficits being specific to only one test of cognitive flexibility. The specific behavioural phenotype seen in this Dlg2+/- model may capture features of the clinical presentation associated with variation in the Dlg2 gene.


Subject(s)
Guanylate Kinases , Learning , Membrane Proteins , Mental Disorders , Humans , Animals , Rats , Membrane Proteins/genetics , Guanylate Kinases/genetics , Cognition , Male , Female , Animals, Outbred Strains , Heterozygote , Mental Disorders/genetics , Hippocampus/physiopathology
3.
Neuropsychopharmacology ; 47(7): 1367-1378, 2022 06.
Article in English | MEDLINE | ID: mdl-35115661

ABSTRACT

Copy number variants indicating loss of function in the DLG2 gene have been associated with markedly increased risk for schizophrenia, autism spectrum disorder, and intellectual disability. DLG2 encodes the postsynaptic scaffolding protein DLG2 (PSD93) that interacts with NMDA receptors, potassium channels, and cytoskeletal regulators but the net impact of these interactions on synaptic plasticity, likely underpinning cognitive impairments associated with these conditions, remains unclear. Here, hippocampal CA1 neuronal excitability and synaptic function were investigated in a novel clinically relevant heterozygous Dlg2+/- rat model using ex vivo patch-clamp electrophysiology, pharmacology, and computational modelling. Dlg2+/- rats had reduced supra-linear dendritic integration of synaptic inputs resulting in impaired associative long-term potentiation. This impairment was not caused by a change in synaptic input since NMDA receptor-mediated synaptic currents were, conversely, increased and AMPA receptor-mediated currents were unaffected. Instead, the impairment in associative long-term potentiation resulted from an increase in potassium channel function leading to a decrease in input resistance, which reduced supra-linear dendritic integration. Enhancement of dendritic excitability by blockade of potassium channels or activation of muscarinic M1 receptors with selective allosteric agonist 77-LH-28-1 reduced the threshold for dendritic integration and 77-LH-28-1 rescued the associative long-term potentiation impairment in the Dlg2+/- rats. These findings demonstrate a biological phenotype that can be reversed by compound classes used clinically, such as muscarinic M1 receptor agonists, and is therefore a potential target for therapeutic intervention.


Subject(s)
Autism Spectrum Disorder , Guanylate Kinases/metabolism , Animals , Autism Spectrum Disorder/metabolism , Hippocampus/metabolism , Long-Term Potentiation/genetics , Membrane Proteins/metabolism , Neuronal Plasticity/genetics , Potassium Channels/metabolism , Rats , Receptors, N-Methyl-D-Aspartate/metabolism , Synapses/physiology , Synaptic Transmission/physiology
4.
Genes Brain Behav ; 21(4): e12797, 2022 04.
Article in English | MEDLINE | ID: mdl-35075790

ABSTRACT

Genetic studies implicate disruption to the DLG2 gene in copy number variants as increasing risk for schizophrenia, autism spectrum disorders and intellectual disability. To investigate psychiatric endophenotypes associated with DLG2 haploinsufficiency (and concomitant PSD-93 protein reduction) a novel clinically relevant Dlg2+/- rat was assessed for abnormalities in anxiety, sensorimotor gating, hedonic reactions, social behaviour, and locomotor response to the N-Methyl-D-aspartic acid receptor antagonist phencyclidine. Dlg gene and protein expression were also investigated to assess model validity. Reductions in PSD-93 messenger RNA and protein were observed in the absence of compensation by other related genes or proteins. Behaviourally Dlg2+/- rats show a potentiated locomotor response to phencyclidine, as is typical of psychotic disorder models, in the absence of deficits in the other behavioural phenotypes assessed here. This shows that the behavioural effects of Dlg2 haploinsufficiency may specifically relate to psychosis vulnerability but are subtle, and partially dissimilar to behavioural deficits previously reported in Dlg2+/- mouse models demonstrating issues surrounding the comparison of models with different aetiology and species. Intact performance on many of the behavioural domains assessed here, such as anxiety and reward processing, will remove these as confounds when continuing investigation into this model using more complex cognitive tasks.


Subject(s)
Guanylate Kinases , Haploinsufficiency , Schizophrenia , Tumor Suppressor Proteins , Animals , Disease Models, Animal , Guanylate Kinases/genetics , Humans , Intracellular Signaling Peptides and Proteins , Membrane Proteins , Mice , Phencyclidine/pharmacology , Rats , Schizophrenia/genetics , Schizophrenia/metabolism , Social Behavior , Tumor Suppressor Proteins/genetics
5.
Psychopharmacology (Berl) ; 237(8): 2381-2394, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32435818

ABSTRACT

RATIONALE: Reward-related impairments are common in major depressive disorder (MDD) and may contribute to the loss of interest in pleasurable activities. A novel approach to studying reward-related decision-making are effort-based tasks; however, direct comparisons between delayed-onset and rapid-acting antidepressants (ADs) have not yet been carried out. OBJECTIVES: To investigate the effects of conventional delayed-onset ADs versus rapid-acting ADs, ketamine and scopolamine, on effort-related choice behaviour. METHODS: Female Lister hooded rats were trained in an operant effort for reward task (EfRT) where animals choose between working for a high value-high effort reward and consuming low value-low effort chow. Using a within-subject study design, animals were then tested following acute treatment with different monoaminergic ADs, and the rapid-acting ADs ketamine or scopolamine. RESULTS: Consistent with previous findings, we found choice behaviour was sensitive to dopaminergic manipulations. We observed that pre-feeding altered choice behaviour and that the use of high or low value reward differentially affected behaviour. Monoamine re-uptake inhibitors and rapid-acting ADs resulted in similar, general patterns of reduced motivation without any evidence for specific effects, and we did not observe any clear differences between these classes of antidepressant. CONCLUSIONS: Motivational changes induced by dopaminergic manipulations and pre-feeding differentially affect effort choice behaviour. However, both conventional delayed-onset ADs and ketamine and scopolamine appear to have detrimental effects on motivation in this task at the higher doses tested without any evidence of specificity for effort-related choice behaviour, in contrast to their specificity in tasks which look at more cognitive aspects of reward processing.


Subject(s)
Antidepressive Agents/administration & dosage , Choice Behavior/drug effects , Motivation/drug effects , Reward , Animals , Choice Behavior/physiology , Decision Making/drug effects , Decision Making/physiology , Delayed-Action Preparations/administration & dosage , Dopamine Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/administration & dosage , Female , Motivation/physiology , Rats , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...